Characteristic | n(%) |
---|---|
Organ involvement | Â |
   Joint contractures | 16 (44%) |
   Esophageal hypomotility | 24 (67%) |
   Cardiac involvement | 1 (3%) |
   Renal involvement | 1 (3%) |
   Interstitial lung disease | 22 (62%) |
   Pulmonary arterial hypertension | 1 (3%) |
   Digital pitting scars | 18 (50%) |
Systemic sclerosis-related autoantibodiesa | Â |
   Anti-topoisomerase I | 16 (44%) |
   Anticentromere | 7 (19%) |
   Anti-RNA polymerase III | 2 (6%) |
   Anti-U1 ribonucleoprotein | 7 (19%) |
   Anti-Th/To | 2 (6%) |
   Not identified | 5 (14%) |
Medications reported when blood samples collected | Â |
   Prednisolone (≤10 mg/day) | 11 (31%) |
   Cyclophosphamide | 1 (3%) |
   Nonsteroidal anti-inflammatory drug | 5 (14%) |
   D-Penicillamine | 3 (8%) |
   Oral prostanoid | 19 (53%) |
   Calcium channel blocker | 2 (6%) |
   Statin | 6 (17%) |
   Anti-platelet aggregation | 6 (17%) |
   Antacid | 12 (33%) |